Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 23, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on October 22, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share repurchases and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (Oct 22): 248,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,625.00p; highest price paid was 1,655.00p.
- Volume-Weighted Average Price (VWAP): 1,644.38p.
- Trading Venues: Purchases were executed across XLON (London Stock Exchange), CHIX, and BATE.
- Programme Progress: Since September 30, 2025, the company has purchased a total of 5,361,500 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 252,826,344 ordinary shares in treasury.
- Shares in Issue: 4,062,590,575 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.22% of total voting rights.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The primary change reported is the reduction in shares outstanding and the increase in treasury shares resulting from the October 22 repurchase activity.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's 2024 Annual Report on Form 20-F and Q2 2025 Results.
Important Facts for Investor Verification
- Verify the total cost of the repurchase programme to date against the company's cash position and liquidity requirements.
- Confirm the remaining authorization limit for the buyback programme, as the filing only states the number of shares purchased since September 30, 2025.
- Note that treasury shares (6.22% of voting rights) do not carry voting rights, which may impact shareholder voting thresholds.
- Review the detailed trade schedule to ensure compliance with market trading rules and the non-discretionary agreement terms.